CALR-mutant blood cancer vaccine for adults with high-risk ET or PMF
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 1 study tests a vaccine made from a CALR mutation (a specific genetic change) to help the immune system recognize and fight your blood cancer. It is mainly focused on early safety and to see if the vaccine can trigger an immune response in people with CALR-mutated myeloproliferative neoplasms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to understand and sign consent
- You must have a chronic myeloproliferative neoplasm in the chronic phase, such as treated/relapsed high-risk essential thrombocythemia (ET), or low–intermediate 1 risk primary myelofibrosis (PMF), including ET-related MF
- Your lab results must confirm a CALR exon 9 mutation
- Blood counts and organ labs must be within required ranges (including minimum white blood cells and platelets, and limits on kidney, liver, and bilirubin tests)
- If you could become pregnant, you must have a negative pregnancy test and use two effective birth-control methods at the same time (or stay abstinent), and you must keep doing pregnancy tests during the study
- If you take hydroxyurea for symptom control, your dose must be stable for at least 8 weeks before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
This study looks at how much of a specific gene change (CALR) you have, and whether it helps doctors diagnose and follow people with certain blood cancers over time. It mainly involves using samples and medical data rather than testing a new drug.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial tests a peptide vaccine combined with an immune booster (XS15) to stop AML from coming back. It is for people who are in remission after treatment but cannot have a stem cell transplant.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.